Immune Checkpoint Inhibitors in Advanced NSCLC: [

IrAEs NSCLC PD-1 [18F]FDG PET/CT immunotherapy treatment response

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
15 Sep 2021
Historique:
received: 23 07 2021
revised: 02 09 2021
accepted: 11 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

The aim of this study was to investigate whether [ Twenty-eight patients who underwent [ The CD was achieved in 54% of patients. Out of 28 eligible patients, 13 (46%) experienced progressive disease (PD), 7 showed SD, 7 had PR, and only in one patient CR was achieved. ΔSUV [

Identifiants

pubmed: 34574022
pii: diagnostics11091681
doi: 10.3390/diagnostics11091681
pmc: PMC8471751
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Commun (Lond). 2021 Apr;41(4):287-302
pubmed: 33689225
Int J Mol Sci. 2017 Sep 09;18(9):
pubmed: 28891933
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32709713
Cancers (Basel). 2020 May 05;12(5):
pubmed: 32380754
Lung Cancer. 2018 Jan;115:71-74
pubmed: 29290265
Cancers (Basel). 2021 Apr 01;13(7):
pubmed: 33915801
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455666
Melanoma Res. 2019 Apr;29(2):178-186
pubmed: 30653029
Clin Lung Cancer. 2019 May;20(3):201-207
pubmed: 30442524
J Thorac Dis. 2019 Nov;11(11):E221-E223
pubmed: 31903287
Sci Rep. 2019 Sep 16;9(1):13362
pubmed: 31527660
Curr Radiopharm. 2020;13(3):177-184
pubmed: 31858908
Cancer Biother Radiopharm. 2021 Mar;36(2):123-132
pubmed: 32551915
Int J Clin Oncol. 2018 Dec;23(6):1052-1059
pubmed: 29948239
Nucl Med Commun. 2019 Aug;40(8):802-807
pubmed: 31045745
Cancer Lett. 2021 Nov 1;520:91-99
pubmed: 34237407
Radiographics. 2021 Jan-Feb;41(1):120-143
pubmed: 33275541
Cytokine. 2021 Feb;138:155363
pubmed: 33264749
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1019-1021
pubmed: 31996974
Molecules. 2021 Apr 11;26(8):
pubmed: 33920423
Diagnostics (Basel). 2017 Feb 15;7(1):
pubmed: 28212290
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii59-vii67
pubmed: 31816080
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075
pubmed: 29532102
Clin Nucl Med. 2019 Apr;44(4):e272-e279
pubmed: 30688730
J Pers Med. 2021 Mar 18;11(3):
pubmed: 33803667
Cancer Med. 2017 Nov;6(11):2552-2561
pubmed: 28980429
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Transl Lung Cancer Res. 2015 Oct;4(5):560-75
pubmed: 26629425

Auteurs

Cristina Ferrari (C)

Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.

Giulia Santo (G)

Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.

Nunzio Merenda (N)

Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.

Alessia Branca (A)

Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.

Paolo Mammucci (P)

Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.

Pamela Pizzutilo (P)

Medical Thoracic Unit, IRCCS Oncologico Giovanni Paolo II, 70124 Bari, Italy.

Cosmo Damiano Gadaleta (CD)

Interventional and Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.

Giuseppe Rubini (G)

Nuclear Medicine Unit, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.

Classifications MeSH